Evidence map›Paper›PMID 42223695›Full record

ArticleBreast cancer research and treatment2026

Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.

Kamaria L Lee, Clinton Yam, Li Zhao, Roland L Bassett, Xingzhi Song, Alastair M Thompson, Jason B White, Rachel M Layman, Lei Huo, Angelica M Gutierrez and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kamaria L LeeDepartment of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Clinton YamDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roland L BassettDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xingzhi SongDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alastair M ThompsonDepartment of Surgical Oncology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Jason B WhiteDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rachel M LaymanDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lei HuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Angelica M GutierrezDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vicente ValeroDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naoto T UenoDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer K LittonDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth RavenbergDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anil KorkutDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beatriz E AdradaDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rosalind P CandelariaDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gaiane M RauchDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Debu TripathyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Simona F ShaitelmanDepartment of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Banu K ArunDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. barun@mdanderson.org.ORCID http://orcid.org/0000-0002-5475-8509

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
CPRIT (RP240293)National Cancer Institute, National Institutes of Health P30CA016672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeMost patients with triple-negative breast cancer (TNBC) undergo neoadjuvant therapy (NAT). Prospective studies on the landscape of non-BRCA germline pathogenic variants (PVs) in patients with TNBC and their impact on response to NAT are sparse.

methodsOn a prospective trial, patients received NAT with doxorubicin and cyclophosphamide with or without immunotherapy followed by paclitaxel with or without carboplatin vs. targeted therapy. Before NAT, DNA was extracted from blood samples and sequenced. Germline variants were identified. Variants deemed deleterious and present in genes found in a 103 pan-cancer susceptibility gene panel were tabulated. Univariate logistic regression models assessed the relationship between variants and pathologic complete response (pCR), pCR and minimal residual cancer burden I (RCB I) as a combined outcome, and radiologic response.

resultsOf 184 patients, 72% were White, 19% were Black, and 8% were Asian. 36% had PVs in pan-cancer susceptibility genes. PVs were found in 31 genes not previously found to have PVs in other known US cohorts. Of 181 patients with NAT response data, 67 (37%) had pCR; 22 (12%), 69 (38%), and 23 (13%) had RCB I, II, and III, respectively. There was no significant difference in pCR rates vs. RCB I/II/III, achievement of a pCR/RCB I vs. RCB II/III, or radiologic response between those with and without a PV.

conclusionOver one-third of patients had germline PVs in pan-cancer susceptibility genes, suggesting multigene panels should be considered. The presence of non-BRCA germline PVs was not associated with a difference in pathologic response.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsGerm-Line MutationTriple Negative Breast NeoplasmsAdultAgedCyclophosphamideFemaleGenetic Predisposition to DiseaseHumansMiddle AgedNeoadjuvant TherapyPathologic Complete ResponseProspective StudiesTreatment OutcomeCyclophosphamideBreast cancerNeoadjuvant therapyPathogenic variantsPathologic complete responseTriple-negative breast cancer

Identifiers

PMID42223695
PMCPMC13226415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.